TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07430059: A Randomized, Parallel-Group Study to Assess the Safety, Tolerability, and Pharmacokinetics of Semaglutide Implant

Sponsor: Vivani Medical, Inc · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$2,076,992

Rescue Site Savings

+$1,377,136

Unlock Full NCT07430059 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07430059 Rescue Dossier →